DDInter57 DDInter1376
An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Altretamine {u} (Compound) treats {v} (Disease) ovarian cancer
Altretamine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
Altretamine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Altretamine {u} (Compound) downregulates {v} (Gene) KRT7
Altretamine {u} (Compound) causes {v} (Side Effect) Leukopenia
Altretamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Altretamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Altretamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Altretamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Altretamine {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Altretamine (Compound) treats ovarian cancer (Disease)
Altretamine (Compound) upregulates ST6GALNAC2 (Gene)
Altretamine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Altretamine (Compound) downregulates KRT7 (Gene)
Altretamine (Compound) causes Leukopenia (Side Effect)
Altretamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Altretamine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam